Test Price
2,800 AED✅ Home Collection Available
DNM1L Gene Encephalopathy, Lethal, Due to Defective Mitochondrial and Peroxisomal Fission – Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين DNM1L للاعتلال الدماغي المميت بسبب خلل الانشطار الميتوكوندري والبيروكسيزومي في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary – Rapid Genetic Confirmation with Uncompromising UAE Compliance
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Next-Generation Sequencing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Paid Hospital-Grade Home Collection (8 AM–11 PM) using ISO Certified Cold-Chain transport. VIP Mobile Phlebotomy included.
- Clinical Guidance: Complimentary telephonic post-test genetic counselling session with interpretation by a DHA-licensed Neurologist and Clinical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp: +971 54 548 8731.
- Regulatory Shield: Full adherence to Federal Decree-Law No. 41 of 2024 (Art. 87), UAE CDS Law 2026 (Minors), and UAE PDPL data privacy.
نقدم تحليلًا جينيًا متقدمًا لجين DNM1L باستخدام تقنية التسلسل من الجيل التالي (NGS) وفقًا لأعلى معايير الجودة والاعتماد من هيئة الصحة بدبي، مع خدمة سحب منزلي معتمدة واستشارة وراثية بعد الفحص.
Overview
The DNM1L gene test leverages high-depth Next-Generation Sequencing to detect pathogenic variants responsible for an ultra-rare, lethal neonatal encephalopathy caused by defective mitochondrial and peroxisomal fission. In the UAE, this test provides families and physicians with a definitive molecular diagnosis within 3 to 4 weeks, enabling informed reproductive decisions and targeted palliative care.
| Feature | Our NGS Test (DHA-Licensed) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Analytical Sensitivity | >99.9% (single-nucleotide & indels) | ~99.0%, limited to targeted exon |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Methodology | NGS (Illumina® platform) with full gene coverage | Capillary electrophoresis, exon-by-exon |
| UAE Regulatory Status | DHA facility license 9834453, ISO 9001:2015 | Often international, unverified local licensing |
Physician Insight & Safety Protocol
“As a DHA-licensed Neurologist, I understand the profound anxiety families experience when facing a suspected lethal encephalopathy. This DNM1L gene test provides a definitive molecular answer, removing diagnostic uncertainty and guiding compassionate clinical decisions. However, results must always be correlated with the full clinical picture and family history; a negative result does not exclude all metabolic disorders.”
Dr. Prabhakar Reddy, DHA License 61713011
⚠️ Medication Warning: Do not discontinue any prescribed medication for the patient without explicit instruction from your treating physician.
Patient Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: Asymptomatic minors without a documented family history of DNM1L-related disease and without pre-test genetic counselling by a certified genetic counsellor (UAE CDS Law 2026).
- Exclusion: Inability to provide informed consent from a legal guardian for minors or from the patient if lacking legal capacity.
- Emergency Red Flag: If the child develops respiratory failure, refractory seizures, or severe metabolic acidosis, seek immediate emergency paediatric care before scheduling the genetic blood draw.
- Counselling Mandate: A pre-test genetic counselling session is mandatory to draw a pedigree chart of family members affected by DNM1L encephalopathy (as per DHA/MOHAP standard).
Sample Requirements & Pre-Test Information
Accepted Samples: Whole Blood (EDTA), Extracted DNA, or One Drop of Blood on FTA Card.
Turnaround Time: 3 to 4 Weeks
Pre-Requisite: A clinical history of the patient and a genetic counselling session to construct a family pedigree of DNM1L-related encephalopathy are required before sample collection.
Home Collection: Daily 8 AM – 11 PM, including weekends. Book via WhatsApp.
Patient FAQ & Clinical Guidance
Q: How is this genetic test different from routine newborn screening?
A: This test uses high-depth NGS to directly sequence the entire DNM1L gene, detecting pathogenic mutations that cause lethal encephalopathy, which is not covered by standard newborn screening panels.
س: كيف يختلف هذا الاختبار الجيني عن فحوصات حديثي الولادة الروتينية؟
ج: يستخدم هذا الاختبار تقنية التسلسل الجيني عالي التغطية لفحص جين DNM1L بالكامل واكتشاف الطفرات المسببة للاعتلال الدماغي المميت، وهو غير مشمول في فحوصات حديثي الولادة القياسية.
Q: What should I do if the test result is positive?
A: A positive result confirms the diagnosis; our post-test telephonic genetic counselling session will guide you on prognosis, family planning, and available supportive care options.
س: ماذا أفعل إذا كانت نتيجة الاختبار إيجابية؟
ج: تؤكد النتيجة الإيجابية التشخيص؛ وتوفر جلسة الاستشارة الوراثية الهاتفية بعد الاختبار إرشادات حول التوقعات الصحية والتخطيط الأسري وخيارات الرعاية الداعمة.
Q: Is this test covered by insurance in the UAE?
A: Many UAE insurers partially or fully cover this DNM1L when pre-authorized; contact our WhatsApp billing verification at +971 54 548 8731 for a direct eligibility check.
س: هل يغطي التأمين هذا الاختبار في الإمارات؟
ج: تغطي العديد من شركات التأمين في الإمارات هذا الاختبار جزئيًا أو كليًا عند الحصول على موافقة مسبقة؛ راسلنا عبر واتساب على الرقم 5488731 (0)971+ للتحقق المباشر من الأهلية.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians